Clinical experience in hematologic malignancies supports these concepts: programs such as CD19/CD22 and CD19/CD37 have reported high response rates with fewer antigen-negative relapses relative to single-antigen approaches 128, 129. The gene discussed is CD19; the disease is hematologic disorder.